blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2579874

EP2579874 - INJECTABLE FLOWABLE COMPOSITION COMPRISING BUPRENORPHINE [Right-click to bookmark this link]
StatusOpposition rejected
Status updated on  09.09.2022
Database last updated on 18.03.2026
FormerThe patent has been granted
Status updated on  08.12.2017
FormerGrant of patent is intended
Status updated on  15.08.2017
FormerExamination is in progress
Status updated on  24.05.2017
Most recent event   Tooltip09.09.2022Opposition rejectedpublished on 12.10.2022  [2022/41]
Applicant(s)For all designated states
Indivior UK Limited
103-105 Bath Road
Slough
Berkshire SL1 3UH / GB
[2015/39]
Former [2013/16]For all designated states
RB Pharmaceuticals Limited
103-105 Bath Road
Slough
Berkshire SL1 3UH / GB
Inventor(s)01 / NORTON, Richard L.
Reckitt Benckiser Pharmaceutical Inc.
2579 Midpoint Drive
Fort Collins
Colorado 80525 / US
02 / WATKINS, Andrew
Reckitt Benckiser Pharmaceutical Inc.
2579 Midpoint Drive
Fort Collins
Colorado 80525 / US
03 / ZHOU, Mingxing
Reckitt Benckiser Pharmaceutical Inc.
2579 Midpoint Drive
Fort Collins
Colorado 80525 / US
 [2013/16]
Representative(s)HGF
HGF Limited
4th Floor, 1 City Square
Leeds LS1 2ES / GB
[N/P]
Former [2018/02]HGF Limited
1 City Walk
Leeds LS11 9DX / GB
Former [2013/16]O'Brien, Niall James, et al
Reckitt Benckiser Corporate Services Limited Legal Department - Patents Group Dansom Lane Hull
HU8 7DS / GB
Application number, filing date11728037.006.06.2011
[2018/02]
WO2011GB51057
Priority number, dateGB2010000954908.06.2010         Original published format: GB 201009549
[2013/16]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2011154724
Date:15.12.2011
Language:EN
[2011/50]
Type: A2 Application without search report 
No.:EP2579874
Date:17.04.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 15.12.2011 takes the place of the publication of the European patent application.
[2013/16]
Type: B1 Patent specification 
No.:EP2579874
Date:10.01.2018
Language:EN
[2018/02]
Search report(s)International search report - published on:EP12.07.2012
ClassificationIPC:A61K47/34, A61K47/22, A61K31/485, A61K9/00
[2017/34]
CPC:
A61K9/0024 (EP,GB,US); A61K9/08 (RU); A61K47/34 (EP,GB,KR,RU,US);
A61K9/0002 (US); A61K31/00 (KR); A61K31/485 (EP,GB,KR,RU,US);
A61K47/06 (KR); A61K47/10 (KR); A61K47/14 (KR);
A61K47/18 (KR); A61K47/22 (KR); A61K47/30 (KR);
A61K9/00 (KR); A61K9/06 (KR); A61P25/04 (EP);
A61P25/36 (EP); A61P29/00 (EP) (-)
Former IPC [2013/16]A61K31/485, A61K47/22, A61K47/34, A61K9/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/16]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:INJIZIERBARE FLIESSFÄHIGE ZUSAMMENSETZUNG MIT BUPRENORPHIN[2013/16]
English:INJECTABLE FLOWABLE COMPOSITION COMPRISING BUPRENORPHINE[2013/16]
French:COMPOSITION FLUIDE INJECTABLE DE BUPRÉNORPHINE[2013/16]
Entry into regional phase03.01.2013National basic fee paid 
03.01.2013Designation fee(s) paid 
03.01.2013Examination fee paid 
Examination procedure03.01.2013Amendment by applicant (claims and/or description)
03.01.2013Examination requested  [2013/16]
25.10.2013Despatch of a communication from the examining division (Time limit: M06)
06.05.2014Reply to a communication from the examining division
30.06.2016Despatch of a communication from the examining division (Time limit: M04)
21.10.2016Reply to a communication from the examining division
15.05.2017Despatch of a communication from the examining division (Time limit: M02)
07.07.2017Reply to a communication from the examining division
16.08.2017Communication of intention to grant the patent
30.11.2017Fee for grant paid
30.11.2017Fee for publishing/printing paid
30.11.2017Receipt of the translation of the claim(s)
Divisional application(s)EP17205986.7  / EP3360538
EP23150636.1  / EP4218720
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.10.2013
Opposition(s)Opponent(s)01  10.10.2018  19.10.2018  ADMISSIBLE
Teva Pharmaceutical Industries Ltd
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 [2021/46]
Former [2021/03]
Opponent(s)01  10.10.2018  19.10.2018  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
Former [2018/48]
Opponent(s)01  10.10.2018  19.10.2018  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
Opponent's representative
Best, Michael
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München / DE
02.11.2018Invitation to proprietor to file observations on the notice of opposition
11.03.2019Reply of patent proprietor to notice(s) of opposition
17.03.2020Cancellation of oral proceeding that was planned for 26.03.2020
26.03.2020Date of oral proceedings
24.09.2020Cancellation of oral proceeding that was planned for 02.11.2020
02.11.2020Date of oral proceedings
27.09.2021Date of oral proceedings
19.10.2021Despatch of minutes of oral proceedings
19.10.2021Date of despatch of rejection of opposition
12.08.2022Legal effect of rejection of opposition [2022/41]
Appeal following opposition05.11.2021Appeal received No.  T1960/21
05.11.2021Payment of appeal fee
16.02.2022Statement of grounds filed
12.08.2022Result of appeal procedure: appeal of the opponent withdrawn
Fees paidRenewal fee
27.06.2013Renewal fee patent year 03
30.06.2014Renewal fee patent year 04
29.06.2015Renewal fee patent year 05
27.06.2016Renewal fee patent year 06
27.06.2017Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Rights in Rem or Legal Means of ExecutionID:01
For:AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Date:08.01.2015
[2015/09]
Lapses during opposition  TooltipAT06.06.2019
CY06.06.2019
CZ06.06.2019
HR06.06.2019
IE06.06.2019
LT06.06.2019
LU06.06.2019
LV06.06.2019
MT06.06.2019
PL06.06.2019
RO06.06.2019
SK06.06.2019
TR06.06.2019
HU07.06.2019
SI07.06.2019
BE30.06.2019
EE30.06.2019
MC01.07.2019
PT06.12.2019
RS09.12.2019
BG31.12.2019
IS31.12.2019
GR07.01.2020
SM13.01.2020
[2022/37]
Former [2022/30]AT06.06.2019
CY06.06.2019
CZ06.06.2019
HR06.06.2019
IE06.06.2019
LT06.06.2019
LU06.06.2019
LV06.06.2019
MT06.06.2019
RO06.06.2019
SK06.06.2019
TR06.06.2019
HU07.06.2019
SI07.06.2019
BE30.06.2019
EE30.06.2019
MC01.07.2019
PT06.12.2019
RS09.12.2019
BG31.12.2019
IS31.12.2019
GR07.01.2020
SM13.01.2020
Former [2022/07]AT06.06.2019
CY06.06.2019
CZ06.06.2019
HR06.06.2019
IE06.06.2019
LT06.06.2019
LU06.06.2019
LV06.06.2019
MT06.06.2019
RO06.06.2019
SK06.06.2019
HU07.06.2019
SI07.06.2019
BE30.06.2019
EE30.06.2019
MC01.07.2019
PT06.12.2019
RS09.12.2019
BG31.12.2019
IS31.12.2019
GR07.01.2020
SM13.01.2020
Former [2020/27]AT06.06.2019
CY06.06.2019
CZ06.06.2019
HR06.06.2019
IE06.06.2019
LT06.06.2019
LU06.06.2019
LV06.06.2019
RO06.06.2019
SK06.06.2019
HU07.06.2019
SI07.06.2019
BE30.06.2019
EE30.06.2019
MC01.07.2019
PT06.12.2019
RS09.12.2019
BG31.12.2019
IS31.12.2019
GR07.01.2020
SM13.01.2020
Former [2020/26]AT06.06.2019
CY06.06.2019
CZ06.06.2019
HR06.06.2019
IE06.06.2019
LT06.06.2019
LU06.06.2019
LV06.06.2019
RO06.06.2019
SK06.06.2019
HU07.06.2019
SI07.06.2019
BE30.06.2019
EE30.06.2019
MC01.07.2019
PT06.12.2019
RS09.12.2019
BG31.12.2019
IS31.12.2019
GR07.01.2020
Former [2020/24]AT06.06.2019
CY06.06.2019
CZ06.06.2019
IE06.06.2019
LT06.06.2019
LV06.06.2019
RO06.06.2019
HU07.06.2019
SI07.06.2019
BE30.06.2019
EE30.06.2019
MC01.07.2019
PT06.12.2019
RS09.12.2019
BG31.12.2019
IS31.12.2019
GR07.01.2020
Former [2020/23]AT06.06.2019
CY06.06.2019
CZ06.06.2019
IE06.06.2019
LT06.06.2019
LV06.06.2019
RO06.06.2019
HU07.06.2019
SI07.06.2019
EE30.06.2019
MC01.07.2019
PT06.12.2019
RS09.12.2019
BG31.12.2019
IS31.12.2019
GR07.01.2020
Former [2020/22]CY06.06.2019
CZ06.06.2019
IE06.06.2019
LT06.06.2019
LV06.06.2019
RO06.06.2019
HU07.06.2019
SI07.06.2019
EE30.06.2019
MC01.07.2019
PT06.12.2019
RS09.12.2019
BG31.12.2019
IS31.12.2019
Former [2020/21]CY06.06.2019
CZ06.06.2019
IE06.06.2019
LT06.06.2019
LV06.06.2019
RO06.06.2019
SI07.06.2019
MC01.07.2019
PT06.12.2019
RS09.12.2019
IS31.12.2019
Former [2020/13]CY06.06.2019
CZ06.06.2019
LT06.06.2019
LV06.06.2019
RO06.06.2019
SI07.06.2019
MC01.07.2019
PT06.12.2019
RS09.12.2019
IS31.12.2019
Former [2020/11]CY06.06.2019
CZ06.06.2019
LT06.06.2019
LV06.06.2019
RO06.06.2019
SI07.06.2019
MC01.07.2019
PT06.12.2019
RS09.12.2019
Former [2020/10]CY06.06.2019
CZ06.06.2019
LT06.06.2019
RO06.06.2019
MC01.07.2019
PT06.12.2019
Former [2020/09]CZ06.06.2019
LT06.06.2019
MC01.07.2019
Former [2020/08]LT06.06.2019
MC01.07.2019
Cited inInternational search[I] WO2009091737  (DUNN RES & CONSULTING LLC et al.)
 [I] WO2004043432  (ALZA CORP et al.)
 [XI]   GRAVES RICHARD A ET AL: "In vitro dissolution method for evaluation of buprenorphine in situ gel formulation: a technical note.", AAPS PHARMSCITECH 2007 LNKD- PUBMED:17915812, vol. 8, no. 3, 2007, pages E1 - E4, XP055025665, ISSN: 1530-9932

DOI:   http://dx.doi.org/10.1208/pt0803062
by applicantUS4938763
 US5278201
 US5324519
 US5702716
 US5744153
 US5990194
 US6461631
 US6565874
   CHOU, TALALAY, ADV. ENZYME REGUL., vol. 22, 1984, pages 27 - 55
   "CONCISE CHEMICAL AND TECHNICAL DICTIONARY", 1986, CHEMICAL PUBLISHING CO., INC., pages: 567
   "CONCISE CHEMICAL AND TECHNICAL DICTIONARY", 1986, CHEMICAL PUBLISHING CO., INC., pages: 707
   "ALDRICH HANDBOOK OF FINE CHEMICALS AND LABORATORY EQUIPMENT", 2000
   LI-HENG PAO ET AL., JOURNAL OF CHROMATOGRAPHY B, vol. 746, 2000, pages 241 - 247
OppositionWO0024374
 WO2008100532
 WO2011154724
   R. A. GRAVES: "In Vitro Dissolution Method for Evaluation of Buprenorphine In Situ Gel Formulation: A Technical Note", AAPS PHARMSCITECH, vol. 8, no. 3, 2007, pages E1 - E4, XP055025665

DOI:   http://dx.doi.org/10.1208/pt0803062
   S. E. ROBINSON: "Buprenorphine: An Analgesic with an Expanding Role in the Treatment of Opioid Addiction", CNS DRUG REVIEWS, vol. 8, no. 4, 2002, pages 377 - 390, XP055523198
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.